Abstracts Archive - Page 2550 of 2607 - ACR Meeting Abstracts

Abstract Number: 801 • 2012 ACR/ARHP Annual Meeting
Symptom Improvement in Fibromyalgia Patients Is Related to Reduced Network Connectivity As Measured by EEG Coherence
Jeffrey B. Hargrove¹, Robert M. Bennett², Daniel J. Clauw³, George Mashour⁴ and Lauren Briggs⁵, ¹Biomedical Engineering, Kettering University, Flint, MI, ²Medicine & Nursing, Oregon Health & Science Univ, Portland, OR, ³Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ⁴Departments of Anesthesiology and Neurosurgery, University of Michigan, Ann Arbor, MI, ⁵Department of Psychology, Grand Valley State University, Allendale, MI
Background/Purpose: To assess changes in brain functional network connectivity (FC) in fibromyalgia (FM) patients treated with Reduced Impedance Noninvasive Cortical Electrostimulation (RINCE). Previous studies using…
Abstract Number: 802 • 2012 ACR/ARHP Annual Meeting
Milnacipran Reduces Brain Activity During Pain in Fibromyalgia
Anson E. Kairys¹, Richard E. Harris², Eric Ichesco², Johnson P. Hampson², Steven Harte², Daniel J. Clauw³ and Tobias Schmidt-Wilcke², ¹Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ²Anesthesiology, University of Michigan, Ann Arbor, MI, ³Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic pain condition characterized by widespread musculoskeletal pain and a number of concomitant symptoms such as fatigue, sleep disturbance, cognitive…
Abstract Number: 803 • 2012 ACR/ARHP Annual Meeting
Frontal Brain Connectivity to the Default Mode Network Is Associated with Subjective Fatigue Irrespective of Pain and Depression
Johnson P. Hampson¹, Daniel J. Clauw², Jieun Kim³, Vitaly Napadow⁴ and Richard E. Harris¹, ¹Anesthesiology, University of Michigan, Ann Arbor, MI, ²Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ³Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, ⁴Radiology, Martinos Center for Biomedical Imaging, Charlestown, MA
Background/Purpose: Chronic pain patients report increased levels of fatigue; however, very little is known about the underlying mechanisms of this symptom. Previous work by our…
Abstract Number: 804 • 2012 ACR/ARHP Annual Meeting
A Comparison of the Nociceptive Flexion Reflex, Pressure Algometry and Summated Widespread Pain in the Diagnosis of Fibromyalgia
Robert M. Bennett¹, Kim D. Jones² and Janice Hoffman³, ¹Medicine & Nursing, Oregon Health & Science Univ, Portland, OR, ²Research & Develop, Oregon Health Sciences University, Portland, OR, ³Office of Research Development & Support, Oregon Health & Science University, Portland, OR
Background/Purpose: To reevaluate the usefulness of the nociceptive flexion reflex (NFR) in distinguishing between FM patients and healthy controls, compared to computerized algometry and a…
Abstract Number: 805 • 2012 ACR/ARHP Annual Meeting
Milnacipran Increases Cortical to Brainstem Connectivity During Pain in Fibromyalgia
Eric Ichesco¹, Tobias Schmidt-Wilcke¹, Anson E. Kairys², Johnson P. Hampson¹, Steven E. Harte¹, Daniel J. Clauw³ and Richard E. Harris¹, ¹Anesthesiology, University of Michigan, Ann Arbor, MI, ²Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ³Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic widespread pain disorder characterized by muscle tenderness, fatigue, poor sleep, and mood disturbance. Milnacipran is a dual serotonin-norepinephrine reuptake…
Abstract Number: 806 • 2012 ACR/ARHP Annual Meeting
Posterior Insula Combined Glutamate and Glutamine Is Associated with Pain in Fibromyalgia: A Replication Study
Eric Ichesco¹, Daniel J. Clauw², Steven E. Harte¹, Anson E. Kairys³, Johnson P. Hampson¹, Tobias Schmidt-Wilcke¹ and Richard E. Harris¹, ¹Anesthesiology, University of Michigan, Ann Arbor, MI, ²Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ³Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI
Background/Purpose: Central pain augmentation resulting from enhanced excitatory and/or decreased inhibitory neurotransmission is a proposed mechanism underlying the pathophysiology of functional pain syndromes such as…
Abstract Number: 807 • 2012 ACR/ARHP Annual Meeting
Predictors of Rheumatoid Arthritis: Quantitative and Semiquantitative Sonographic Measurements of Peripheral Joints
Flavia S. Machado¹, Rita N.V. Furtado¹, Rogerio D. Takahashi², Ana Leticia P. de Buosi¹ and Jamil Natour¹, ¹Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, ²Radiology, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Sonographic quantitative and semiquantitative measurements in peripheral joints of normal subjects are yet to be defined, as are sonographic predictors of rheumatoid arthritis (RA).…
Abstract Number: 808 • 2012 ACR/ARHP Annual Meeting
Power Doppler Is Predictive of Treatment Failure in Early Rheumatoid Arthritis Patients: A One Year Follow-up Study
Karine R. Luz¹, Rita N.V. Furtado¹, Marcelo M. Pinheiro², Giovanna S. Petterle¹ and Jamil Natour¹, ¹Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ²Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: It is known that ultrasound (US) is a useful test to monitor rheumatoid arthritis (RA) patients. However, to date, no study has shown the…
Abstract Number: 809 • 2012 ACR/ARHP Annual Meeting
Ultrasonography Predicts Achievement of Deeper Remission After DAS28-Based Clinical Remission of Rheumatoid Arthritis
Ryusuke Yoshimi¹, Maasa Hama¹, Daiga Kishimoto¹, Reikou Watanabe¹, Takeaki Uehara², Yukiko Asami¹, Atsushi Ihata¹, Atsuhisa Ueda¹, Mitsuhiro Takeno¹ and Yoshiaki Ishigatsubo¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatology, Chigasaki Municipal Hospital, Chigasaki, Japan
Background/Purpose: Although clinical remission is an agreeable goal of treatment in rheumatoid arthritis (RA), the definition is still controversial. Indeed, progressive structural damage is often…
Abstract Number: 810 • 2012 ACR/ARHP Annual Meeting
Assessment of Omeract Global Power Doppler Ultrasonography 44-Joint Scoring System and Reduced Joint Scoring Systems in Rheumatoid Arthritis Patients Treated with Abatacept Plus Background Methotrexate
MA D'Agostino¹, R. Wakefield², H. Berner Hammer³, O. Vittecoq⁴, M. Galeazzi⁵, P. Balint⁶, E. Filippucci⁷, I. Moller⁸, A. Iagnocco⁹, E. Naredo¹⁰, Mikkel Ostergaard¹¹, C. Gaillez¹², K. Van Holder¹³, M. Le Bars¹² and OMERACT-US Task Force¹⁴, ¹AP-HP Ambroise Pare Hospital, Boulogne-Billancourt, France, ²University of Leeds, Leeds, United Kingdom, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University Hospital, Rouen, France, ⁵University of Siena, Siena, Italy, ⁶National Institute, Budapest, Hungary, ⁷University Politecnica delle Marche, Ancona, Italy, ⁸Instituto Poal, Barcelona, Spain, ⁹Sapienza Università di Roma, Roma, Italy, ¹⁰Hospital Severo Ochoa, Madrid, Spain, ¹¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ¹²Bristol-Myers Squibb, Rueil Malmaison, France, ¹³Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ¹⁴Paris
Background/Purpose: The first international trial using the standardized global OMERACT Power Doppler Ultrasonography (PDUS) synovitis scoring system1 showed early and significant signs of improvement in…
Abstract Number: 811 • 2012 ACR/ARHP Annual Meeting
The Relationship Between Power Doppler Ultrasonography Outcomes and Clinical Efficacy in Abatacept-Treated Patients with Rheumatoid Arthritis and in Inadequate Response to Methotrexate
MA D'Agostino¹, R. Wakefield², H. Berner Hammer³, O. Vittecoq⁴, M. Galeazzi⁵, P. Balint⁶, E. Filippucci⁷, I. Moller⁸, A. Iagnocco⁹, E. Naredo¹⁰, Mikkel Ostergaard¹¹, C. Gaillez¹², K. Van Holder¹³, M. Le Bars¹² and OMERACT Ultrasound Task Force¹⁴, ¹AP-HP Ambroise Pare Hospital, Boulogne-Billancourt, France, ²University of Leeds, Leeds, United Kingdom, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University Hospital, Rouen, France, ⁵University of Siena, Siena, Italy, ⁶National Institute, Budapest, Hungary, ⁷University Politecnica delle Marche, Ancona, Italy, ⁸Instituto Poal, Barcelona, Spain, ⁹Sapienza Università di Roma, Roma, Italy, ¹⁰Hospital Severo Ochoa, Madrid, Spain, ¹¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ¹²Bristol-Myers Squibb, Rueil Malmaison, France, ¹³Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ¹⁴Paris
Background/Purpose: An exploratory study using the standardized global OMERACT Power Doppler Ultrasonography (PDUS) scoring system1 in patients (pts) with established RA and inadequate response to…
Abstract Number: 812 • 2012 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial
Michael Weinblatt¹, Clifton O. Bingham III², Alan Mendelsohn³, Lenore Noonan⁴, Shihong Sheng⁵, Lilianne Kim⁶, Kim Hung⁶, Jiandong Lu⁶, Daniel Baker⁶ and Rene Westhovens⁷, ¹Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ²Department of Medicine, Johns Hopkins University, Baltimore, MD, ³Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁴Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁵Biostatistics, Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase…
Abstract Number: 773 • 2012 ACR/ARHP Annual Meeting
Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
Josef S. Smolen¹, D. Aletaha², D. Gruben³, J. D. Bradley⁴, S. H. Zwillich³, S. Krishnaswami³, B. Benda⁵ and C. Mebus⁶, ¹Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Pfizer Inc., Groton, CT, ⁴Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ⁵Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This analysis evaluated the rates…
Abstract Number: 774 • 2012 ACR/ARHP Annual Meeting
A CD4+ T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis
Arthur G. Pratt¹, Philip M. Brown², Simon J. Cockell³, Gillian Wilson⁴ and John D. Isaacs¹, ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom, ³Bioinformatics Unit, Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁴Directorate of Musculoskeletal Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
Background/Purpose: The mechanism of action of methotrexate (MTX) in the management of rheumatoid arthritis (RA) remains incompletely understood. It is nonetheless capable of inducing clinical…
Abstract Number: 775 • 2012 ACR/ARHP Annual Meeting
Long-Term Outcomes of Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach
Roy Fleischmann¹, Ronald F. van Vollenhoven², Josef S. Smolen³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita S. Rathmann⁶, Hartmut Kupper⁷ and Arthur Kavanaugh⁸, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Karolinska Institute, Stockholm, Sweden, ³Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁵AbbVie, Rungis, France, ⁶Abbott, Abbott Park, IL, ⁷Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁸UCSD School of Medicine, La Jolla, CA
Background/Purpose: In rheumatoid arthritis (RA), anti-TNF therapy is considered following 3-6 months of failed methotrexate (MTX) treatment. Some patients (pts), particularly those with many risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].